Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National Surveillance of Enterovirus D68 Upsurge, France, 2024.

Emerging infectious diseases·2026
Same author

Why Andes hantavirus is not the next SARS-CoV-2: contrasting viral shedding, transmissibility and genomic patterns.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Proactive vs. reactive COVID-19 screening in schools: Lessons from experimental protocols in France during the Delta and Omicron waves.

PNAS nexus·2026
Same author

Sante publique (Vandoeuvre-les-Nancy, France)·2026
Same author

Comparison between metatranscriptomics and viral metagenomics, 16S, and host transcriptomics for comprehensive profiling of the respiratory microbiome and host response.

Frontiers in microbiology·2026
Same author

Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

Related Experiment Video

Updated: May 19, 2026

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
10:40

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

Blocking human enterovirus 71 replication by targeting viral 2A protease.

Nisrine Falah1, Roland Montserret, Virginie Lelogeais

  • 1VirPath, Virologie et Pathologie Humaine, EA4610, Université Lyon 1, Université de Lyon, Faculté de Médecine Lyon-Est, secteur Laennec, Rue Guillaume Paradin, F-69372 Lyon cedex 08, France.

The Journal of Antimicrobial Chemotherapy
|August 7, 2012
PubMed
Summary

A peptide inhibitor, LVLQTM, previously effective against human rhinovirus (HRV), also inhibits human enterovirus 71 (EV-71) 2A protease (2A(pro)) and EV-71 replication. This finding offers a potential new antiviral strategy for EV-71 infections.

More Related Videos

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus
11:28

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus

Published on: October 7, 2011

Related Experiment Videos

Last Updated: May 19, 2026

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
10:40

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus
11:28

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus

Published on: October 7, 2011

Area of Science:

  • Virology
  • Molecular Biology
  • Drug Discovery

Background:

  • Human enterovirus 71 (EV-71) is a significant public health concern in the Asia-Pacific, causing severe neurological complications.
  • Currently, no effective vaccines or antiviral treatments exist for EV-71.
  • The six-amino acid peptide LVLQTM has demonstrated inhibitory activity against human rhinovirus (HRV) 2A protease (2A(pro)) and HRV replication.

Purpose of the Study:

  • To evaluate the broader antiviral potential of the LVLQTM peptide against enteroviruses.
  • Specifically, to determine if LVLQTM can inhibit EV-71 2A(pro) activity and EV-71 replication.

Main Methods:

  • A recombinant luciferase assay was developed to assess if LVLQTM acts as a pseudosubstrate for EV-71 2A(pro).
  • Isothermal titration calorimetry confirmed direct interaction between EV-71 2A(pro) and the LVLQTM peptide.
  • The peptide's effect on EV-71 2A(pro) cleavage activity and viral replication in HeLa cells was tested.

Main Results:

  • The LVLQTM peptide functions as a substrate analogue for EV-71 2A(pro), binding to the active site with a dissociation constant of 9.6 μM.
  • LVLQTM significantly inhibited the cleavage activity of EV-71 2A(pro) on eIF4G.
  • Replication of EV-71 in HeLa cells was substantially inhibited by the LVLQTM peptide.

Conclusions:

  • The LVLQTM peptide is a potent inhibitor of EV-71 2A(pro) and effectively suppresses EV-71 replication.
  • This study highlights the potential of LVLQTM as a lead compound for developing novel antiviral therapies against EV-71.
  • The findings suggest a broader applicability of this peptide inhibitor across different enteroviruses.